Loading…
Two hits to the renin‐angiotensin system may play a key role in severe COVID‐19
The spike glycoprotein on the virion surface docking onto the angiotensin‐converting enzyme (ACE) 2 dimer is an essential step in the process of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection in human cells—involves downregulation of ACE2 expression with systemic renin‐angiot...
Saved in:
Published in: | The Kaohsiung journal of medical sciences 2020-06, Vol.36 (6), p.389-392 |
---|---|
Main Authors: | , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c5817-7d2c540245aa7b73f070e1f08ac21c377b57a74f9e705a5a0e273bc9dbbf7f9f3 |
---|---|
cites | cdi_FETCH-LOGICAL-c5817-7d2c540245aa7b73f070e1f08ac21c377b57a74f9e705a5a0e273bc9dbbf7f9f3 |
container_end_page | 392 |
container_issue | 6 |
container_start_page | 389 |
container_title | The Kaohsiung journal of medical sciences |
container_volume | 36 |
creator | Tseng, Yu‐Hsin Yang, Rei‐Cheng Lu, Tzong‐Shi |
description | The spike glycoprotein on the virion surface docking onto the angiotensin‐converting enzyme (ACE) 2 dimer is an essential step in the process of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection in human cells—involves downregulation of ACE2 expression with systemic renin‐angiotensin system (RAS) imbalance and promotion of multi‐organ damage. In general, the RAS induces vasoconstriction, hypertension, inflammation, fibrosis, and proliferation via the ACE/Ang II/Ang II type 1 receptor (AT1R) axis and induces the opposite effects via the ACE2/Ang (1‐7)/Mas axis. The RAS may be activated by chronic inflammation in hypertension, diabetes, obesity, and cancer. SARS‐CoV‐2 induces the ACE2 internalization and shedding, leading to the inactivation of the ACE2/Ang (1‐7)/Mas axis. Therefore, we hypothesize that two hits to the RAS drives COVID‐19 progression. In brief, the first hit originates from chronic inflammation activating the ACE/Ang II/AT1R axis, and the second originates from the COVID‐19 infection inactivating the ACE2/Ang (1‐7)/Mas axis. Moreover, the two hits to the RAS may be the primary reason for increased mortality in patients with COVID‐19 who have comorbidities and may serve as a therapeutic target for COVID‐19 treatment. |
doi_str_mv | 10.1002/kjm2.12237 |
format | article |
fullrecord | <record><control><sourceid>gale_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_d6f1583bd3f24cb08845e10fdc21f841</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A721986744</galeid><doaj_id>oai_doaj_org_article_d6f1583bd3f24cb08845e10fdc21f841</doaj_id><sourcerecordid>A721986744</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5817-7d2c540245aa7b73f070e1f08ac21c377b57a74f9e705a5a0e273bc9dbbf7f9f3</originalsourceid><addsrcrecordid>eNp9ksFuEzEQQFcIRNPChQ9AlrggpATba6-9F6QqUAgU9UBB3Cyvd5w43bVTe9MqNz6Bb-RLcJpSCELIki2N37zRjKYonhA8IRjTlxfLnk4IpaW4V4woI3gsK47vFyNSYTHmnHw9KA5TWmLMqroWD4uDkrKa0pqOik_n1wEt3JDQENCwABTBO__j23ft5y4M4JPzKG3SAD3q9QatunxpdAEbFEMHaPsLVxABTc--zF7nRFI_Kh5Y3SV4fPseFZ9P3pxP341Pz97OpsenY8MlEWPRUsMZpoxrLRpRWiwwEIulNpSYUoiGCy2YrUFgrrnGQEXZmLptGitsbcujYrbztkEv1Sq6XseNCtqpm0CIc6Xj4EwHqq0s4bJs2tJSZhosJeNAsG1zKSsZya5XO9dq3fTQGvBD1N2edP_Hu4WahyslSoyF2Aqe3wpiuFxDGlTvkoGu0x7COinKcF2xqmQyo8_-QpdhHX0eVaYyJzGX_Dc117kB523Idc1Wqo4FJbWsBGOZmvyDyqeF3pngwboc30t4sUswMaQUwd71SLDarpParpO6WacMP_1zKnfor_3JANkB17nM5j8q9eH9R7qT_gQnMNPJ</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2424080585</pqid></control><display><type>article</type><title>Two hits to the renin‐angiotensin system may play a key role in severe COVID‐19</title><source>Publicly Available Content Database (Proquest) (PQ_SDU_P3)</source><source>Wiley_OA刊</source><source>Coronavirus Research Database</source><creator>Tseng, Yu‐Hsin ; Yang, Rei‐Cheng ; Lu, Tzong‐Shi</creator><creatorcontrib>Tseng, Yu‐Hsin ; Yang, Rei‐Cheng ; Lu, Tzong‐Shi</creatorcontrib><description>The spike glycoprotein on the virion surface docking onto the angiotensin‐converting enzyme (ACE) 2 dimer is an essential step in the process of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection in human cells—involves downregulation of ACE2 expression with systemic renin‐angiotensin system (RAS) imbalance and promotion of multi‐organ damage. In general, the RAS induces vasoconstriction, hypertension, inflammation, fibrosis, and proliferation via the ACE/Ang II/Ang II type 1 receptor (AT1R) axis and induces the opposite effects via the ACE2/Ang (1‐7)/Mas axis. The RAS may be activated by chronic inflammation in hypertension, diabetes, obesity, and cancer. SARS‐CoV‐2 induces the ACE2 internalization and shedding, leading to the inactivation of the ACE2/Ang (1‐7)/Mas axis. Therefore, we hypothesize that two hits to the RAS drives COVID‐19 progression. In brief, the first hit originates from chronic inflammation activating the ACE/Ang II/AT1R axis, and the second originates from the COVID‐19 infection inactivating the ACE2/Ang (1‐7)/Mas axis. Moreover, the two hits to the RAS may be the primary reason for increased mortality in patients with COVID‐19 who have comorbidities and may serve as a therapeutic target for COVID‐19 treatment.</description><identifier>ISSN: 1607-551X</identifier><identifier>EISSN: 2410-8650</identifier><identifier>DOI: 10.1002/kjm2.12237</identifier><identifier>PMID: 32492292</identifier><language>eng</language><publisher>BP, Asia: Wiley Publishing Asia Pty Ltd</publisher><subject>Angiotensin converting enzyme ; Angiotensin II - physiology ; Angiotensin Receptor Antagonists - therapeutic use ; Angiotensin-Converting Enzyme 2 ; Angiotensin-Converting Enzyme Inhibitors - therapeutic use ; Betacoronavirus - pathogenicity ; Betacoronavirus - physiology ; Blood pressure ; Cancer ; Cardiovascular disease ; Cells ; Comorbidity ; Conflicts of interest ; coronavirus disease 2019 ; Coronavirus Infections - drug therapy ; Coronavirus Infections - epidemiology ; Coronavirus Infections - physiopathology ; Coronaviruses ; COVID-19 ; Diabetes ; Health aspects ; Humans ; Hypertension ; Infections ; Inflammation ; Inflammatory diseases ; Kinases ; Medical prognosis ; Models, Biological ; Mortality ; Multiple organ dysfunction syndrome ; Obesity ; Pandemics ; Peptidyl-Dipeptidase A - physiology ; Pneumonia, Viral - drug therapy ; Pneumonia, Viral - epidemiology ; Pneumonia, Viral - physiopathology ; Proteins ; Receptor, Angiotensin, Type 1 - physiology ; Renin-Angiotensin System - drug effects ; Renin-Angiotensin System - physiology ; renin‐angiotensin system ; Review ; SARS-CoV-2 ; Severe acute respiratory syndrome ; Signal transduction ; Spike Glycoprotein, Coronavirus - physiology ; two hits</subject><ispartof>The Kaohsiung journal of medical sciences, 2020-06, Vol.36 (6), p.389-392</ispartof><rights>2020 The Authors. published by John Wiley & Sons Australia on behalf of Kaohsiung Medical University.</rights><rights>2020 The Authors. The Kaohsiung Journal of Medical Sciences published by John Wiley & Sons Australia on behalf of Kaohsiung Medical University.</rights><rights>COPYRIGHT 2020 John Wiley & Sons, Inc.</rights><rights>2020. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5817-7d2c540245aa7b73f070e1f08ac21c377b57a74f9e705a5a0e273bc9dbbf7f9f3</citedby><cites>FETCH-LOGICAL-c5817-7d2c540245aa7b73f070e1f08ac21c377b57a74f9e705a5a0e273bc9dbbf7f9f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2424080585?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2424080585?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,780,784,885,11562,25753,27924,27925,37012,37013,38516,43895,44590,46052,46476,74412,75126</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32492292$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tseng, Yu‐Hsin</creatorcontrib><creatorcontrib>Yang, Rei‐Cheng</creatorcontrib><creatorcontrib>Lu, Tzong‐Shi</creatorcontrib><title>Two hits to the renin‐angiotensin system may play a key role in severe COVID‐19</title><title>The Kaohsiung journal of medical sciences</title><addtitle>Kaohsiung J Med Sci</addtitle><description>The spike glycoprotein on the virion surface docking onto the angiotensin‐converting enzyme (ACE) 2 dimer is an essential step in the process of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection in human cells—involves downregulation of ACE2 expression with systemic renin‐angiotensin system (RAS) imbalance and promotion of multi‐organ damage. In general, the RAS induces vasoconstriction, hypertension, inflammation, fibrosis, and proliferation via the ACE/Ang II/Ang II type 1 receptor (AT1R) axis and induces the opposite effects via the ACE2/Ang (1‐7)/Mas axis. The RAS may be activated by chronic inflammation in hypertension, diabetes, obesity, and cancer. SARS‐CoV‐2 induces the ACE2 internalization and shedding, leading to the inactivation of the ACE2/Ang (1‐7)/Mas axis. Therefore, we hypothesize that two hits to the RAS drives COVID‐19 progression. In brief, the first hit originates from chronic inflammation activating the ACE/Ang II/AT1R axis, and the second originates from the COVID‐19 infection inactivating the ACE2/Ang (1‐7)/Mas axis. Moreover, the two hits to the RAS may be the primary reason for increased mortality in patients with COVID‐19 who have comorbidities and may serve as a therapeutic target for COVID‐19 treatment.</description><subject>Angiotensin converting enzyme</subject><subject>Angiotensin II - physiology</subject><subject>Angiotensin Receptor Antagonists - therapeutic use</subject><subject>Angiotensin-Converting Enzyme 2</subject><subject>Angiotensin-Converting Enzyme Inhibitors - therapeutic use</subject><subject>Betacoronavirus - pathogenicity</subject><subject>Betacoronavirus - physiology</subject><subject>Blood pressure</subject><subject>Cancer</subject><subject>Cardiovascular disease</subject><subject>Cells</subject><subject>Comorbidity</subject><subject>Conflicts of interest</subject><subject>coronavirus disease 2019</subject><subject>Coronavirus Infections - drug therapy</subject><subject>Coronavirus Infections - epidemiology</subject><subject>Coronavirus Infections - physiopathology</subject><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>Diabetes</subject><subject>Health aspects</subject><subject>Humans</subject><subject>Hypertension</subject><subject>Infections</subject><subject>Inflammation</subject><subject>Inflammatory diseases</subject><subject>Kinases</subject><subject>Medical prognosis</subject><subject>Models, Biological</subject><subject>Mortality</subject><subject>Multiple organ dysfunction syndrome</subject><subject>Obesity</subject><subject>Pandemics</subject><subject>Peptidyl-Dipeptidase A - physiology</subject><subject>Pneumonia, Viral - drug therapy</subject><subject>Pneumonia, Viral - epidemiology</subject><subject>Pneumonia, Viral - physiopathology</subject><subject>Proteins</subject><subject>Receptor, Angiotensin, Type 1 - physiology</subject><subject>Renin-Angiotensin System - drug effects</subject><subject>Renin-Angiotensin System - physiology</subject><subject>renin‐angiotensin system</subject><subject>Review</subject><subject>SARS-CoV-2</subject><subject>Severe acute respiratory syndrome</subject><subject>Signal transduction</subject><subject>Spike Glycoprotein, Coronavirus - physiology</subject><subject>two hits</subject><issn>1607-551X</issn><issn>2410-8650</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>COVID</sourceid><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNp9ksFuEzEQQFcIRNPChQ9AlrggpATba6-9F6QqUAgU9UBB3Cyvd5w43bVTe9MqNz6Bb-RLcJpSCELIki2N37zRjKYonhA8IRjTlxfLnk4IpaW4V4woI3gsK47vFyNSYTHmnHw9KA5TWmLMqroWD4uDkrKa0pqOik_n1wEt3JDQENCwABTBO__j23ft5y4M4JPzKG3SAD3q9QatunxpdAEbFEMHaPsLVxABTc--zF7nRFI_Kh5Y3SV4fPseFZ9P3pxP341Pz97OpsenY8MlEWPRUsMZpoxrLRpRWiwwEIulNpSYUoiGCy2YrUFgrrnGQEXZmLptGitsbcujYrbztkEv1Sq6XseNCtqpm0CIc6Xj4EwHqq0s4bJs2tJSZhosJeNAsG1zKSsZya5XO9dq3fTQGvBD1N2edP_Hu4WahyslSoyF2Aqe3wpiuFxDGlTvkoGu0x7COinKcF2xqmQyo8_-QpdhHX0eVaYyJzGX_Dc117kB523Idc1Wqo4FJbWsBGOZmvyDyqeF3pngwboc30t4sUswMaQUwd71SLDarpParpO6WacMP_1zKnfor_3JANkB17nM5j8q9eH9R7qT_gQnMNPJ</recordid><startdate>202006</startdate><enddate>202006</enddate><creator>Tseng, Yu‐Hsin</creator><creator>Yang, Rei‐Cheng</creator><creator>Lu, Tzong‐Shi</creator><general>Wiley Publishing Asia Pty Ltd</general><general>John Wiley & Sons, Inc</general><general>Wiley</general><scope>24P</scope><scope>WIN</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>COVID</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>202006</creationdate><title>Two hits to the renin‐angiotensin system may play a key role in severe COVID‐19</title><author>Tseng, Yu‐Hsin ; Yang, Rei‐Cheng ; Lu, Tzong‐Shi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5817-7d2c540245aa7b73f070e1f08ac21c377b57a74f9e705a5a0e273bc9dbbf7f9f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Angiotensin converting enzyme</topic><topic>Angiotensin II - physiology</topic><topic>Angiotensin Receptor Antagonists - therapeutic use</topic><topic>Angiotensin-Converting Enzyme 2</topic><topic>Angiotensin-Converting Enzyme Inhibitors - therapeutic use</topic><topic>Betacoronavirus - pathogenicity</topic><topic>Betacoronavirus - physiology</topic><topic>Blood pressure</topic><topic>Cancer</topic><topic>Cardiovascular disease</topic><topic>Cells</topic><topic>Comorbidity</topic><topic>Conflicts of interest</topic><topic>coronavirus disease 2019</topic><topic>Coronavirus Infections - drug therapy</topic><topic>Coronavirus Infections - epidemiology</topic><topic>Coronavirus Infections - physiopathology</topic><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>Diabetes</topic><topic>Health aspects</topic><topic>Humans</topic><topic>Hypertension</topic><topic>Infections</topic><topic>Inflammation</topic><topic>Inflammatory diseases</topic><topic>Kinases</topic><topic>Medical prognosis</topic><topic>Models, Biological</topic><topic>Mortality</topic><topic>Multiple organ dysfunction syndrome</topic><topic>Obesity</topic><topic>Pandemics</topic><topic>Peptidyl-Dipeptidase A - physiology</topic><topic>Pneumonia, Viral - drug therapy</topic><topic>Pneumonia, Viral - epidemiology</topic><topic>Pneumonia, Viral - physiopathology</topic><topic>Proteins</topic><topic>Receptor, Angiotensin, Type 1 - physiology</topic><topic>Renin-Angiotensin System - drug effects</topic><topic>Renin-Angiotensin System - physiology</topic><topic>renin‐angiotensin system</topic><topic>Review</topic><topic>SARS-CoV-2</topic><topic>Severe acute respiratory syndrome</topic><topic>Signal transduction</topic><topic>Spike Glycoprotein, Coronavirus - physiology</topic><topic>two hits</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tseng, Yu‐Hsin</creatorcontrib><creatorcontrib>Yang, Rei‐Cheng</creatorcontrib><creatorcontrib>Lu, Tzong‐Shi</creatorcontrib><collection>Wiley_OA刊</collection><collection>Wiley-Blackwell Free Backfiles(OpenAccess)</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest_Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Coronavirus Research Database</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content Database (Proquest) (PQ_SDU_P3)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Open Access: DOAJ - Directory of Open Access Journals</collection><jtitle>The Kaohsiung journal of medical sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tseng, Yu‐Hsin</au><au>Yang, Rei‐Cheng</au><au>Lu, Tzong‐Shi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Two hits to the renin‐angiotensin system may play a key role in severe COVID‐19</atitle><jtitle>The Kaohsiung journal of medical sciences</jtitle><addtitle>Kaohsiung J Med Sci</addtitle><date>2020-06</date><risdate>2020</risdate><volume>36</volume><issue>6</issue><spage>389</spage><epage>392</epage><pages>389-392</pages><issn>1607-551X</issn><eissn>2410-8650</eissn><abstract>The spike glycoprotein on the virion surface docking onto the angiotensin‐converting enzyme (ACE) 2 dimer is an essential step in the process of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection in human cells—involves downregulation of ACE2 expression with systemic renin‐angiotensin system (RAS) imbalance and promotion of multi‐organ damage. In general, the RAS induces vasoconstriction, hypertension, inflammation, fibrosis, and proliferation via the ACE/Ang II/Ang II type 1 receptor (AT1R) axis and induces the opposite effects via the ACE2/Ang (1‐7)/Mas axis. The RAS may be activated by chronic inflammation in hypertension, diabetes, obesity, and cancer. SARS‐CoV‐2 induces the ACE2 internalization and shedding, leading to the inactivation of the ACE2/Ang (1‐7)/Mas axis. Therefore, we hypothesize that two hits to the RAS drives COVID‐19 progression. In brief, the first hit originates from chronic inflammation activating the ACE/Ang II/AT1R axis, and the second originates from the COVID‐19 infection inactivating the ACE2/Ang (1‐7)/Mas axis. Moreover, the two hits to the RAS may be the primary reason for increased mortality in patients with COVID‐19 who have comorbidities and may serve as a therapeutic target for COVID‐19 treatment.</abstract><cop>BP, Asia</cop><pub>Wiley Publishing Asia Pty Ltd</pub><pmid>32492292</pmid><doi>10.1002/kjm2.12237</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1607-551X |
ispartof | The Kaohsiung journal of medical sciences, 2020-06, Vol.36 (6), p.389-392 |
issn | 1607-551X 2410-8650 |
language | eng |
recordid | cdi_doaj_primary_oai_doaj_org_article_d6f1583bd3f24cb08845e10fdc21f841 |
source | Publicly Available Content Database (Proquest) (PQ_SDU_P3); Wiley_OA刊; Coronavirus Research Database |
subjects | Angiotensin converting enzyme Angiotensin II - physiology Angiotensin Receptor Antagonists - therapeutic use Angiotensin-Converting Enzyme 2 Angiotensin-Converting Enzyme Inhibitors - therapeutic use Betacoronavirus - pathogenicity Betacoronavirus - physiology Blood pressure Cancer Cardiovascular disease Cells Comorbidity Conflicts of interest coronavirus disease 2019 Coronavirus Infections - drug therapy Coronavirus Infections - epidemiology Coronavirus Infections - physiopathology Coronaviruses COVID-19 Diabetes Health aspects Humans Hypertension Infections Inflammation Inflammatory diseases Kinases Medical prognosis Models, Biological Mortality Multiple organ dysfunction syndrome Obesity Pandemics Peptidyl-Dipeptidase A - physiology Pneumonia, Viral - drug therapy Pneumonia, Viral - epidemiology Pneumonia, Viral - physiopathology Proteins Receptor, Angiotensin, Type 1 - physiology Renin-Angiotensin System - drug effects Renin-Angiotensin System - physiology renin‐angiotensin system Review SARS-CoV-2 Severe acute respiratory syndrome Signal transduction Spike Glycoprotein, Coronavirus - physiology two hits |
title | Two hits to the renin‐angiotensin system may play a key role in severe COVID‐19 |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T08%3A07%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Two%20hits%20to%20the%20renin%E2%80%90angiotensin%20system%20may%20play%20a%20key%20role%20in%20severe%20COVID%E2%80%9019&rft.jtitle=The%20Kaohsiung%20journal%20of%20medical%20sciences&rft.au=Tseng,%20Yu%E2%80%90Hsin&rft.date=2020-06&rft.volume=36&rft.issue=6&rft.spage=389&rft.epage=392&rft.pages=389-392&rft.issn=1607-551X&rft.eissn=2410-8650&rft_id=info:doi/10.1002/kjm2.12237&rft_dat=%3Cgale_doaj_%3EA721986744%3C/gale_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c5817-7d2c540245aa7b73f070e1f08ac21c377b57a74f9e705a5a0e273bc9dbbf7f9f3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2424080585&rft_id=info:pmid/32492292&rft_galeid=A721986744&rfr_iscdi=true |